

# SBA ACADEMY

Program 2013

## Challenges in Drug Discovery and Development

**February 22, 2013**

Drug Discovery  
Technologiepark, Basel

**March 22, 2013**

Non-Clinical Development  
Biopôle, Lausanne

**April 26, 2013**

Manufacturing  
Technologiepark, Basel

**May 24, 2013**


Clinical Development  
Biopôle, Lausanne

**June 28, 2013**

Strategy Day  
Technopark, Zürich

Event Partners:

**swiTT**   
swiss technology transfer association

 Schweizerische Eidgenossenschaft  
Confédération suisse  
Confederazione Svizzera  
Confederaziun svizra  
**Förderagentur für Innovation KTI**

Event Organizer:

Swiss Biotech Association, Wengistrasse 7, 8004 Zürich  
info@swissbiotech.org · www.swissbiotech.org

The SBA Academy is supported by:



Strategic partner:

**BIOCOM AG**

# SBA ACADEMY

## Program Module 1: Drug Discovery



Basel, Technologiepark, February 22, 2013













Register at: [www.swissbiotech.org/anmeldungen/challenges\\_in\\_drug\\_discovery\\_and\\_development](http://www.swissbiotech.org/anmeldungen/challenges_in_drug_discovery_and_development)

Fee for members of SBA, switt, CTI start-up companies and academia: CHF 150/module, CHF 750 for full package.

Fee for all others: CHF 950/module, CHF 3'800 for full package.

Contact: Swiss Biotech Association, Wengistrasse 7, 8004 Zürich, [bihlmann@swissbiotech.org](mailto:bihlmann@swissbiotech.org)



Time	Title	Speaker
8:30–10:15	Registration	
Introductory Keynote		
9:00	Pharma R&D: Issues and Perspectives	 <b>Reto Naef</b> Novartis Pharma
9:45	Breakfast & Networking	
Target Identification & Drug Design		
10:15	Bioinformatics, Structure-Activity Relation, Docking Characteristics	 <b>Angelo Vedani</b> University of Basel
		 <b>Torsten Schwede</b> University of Basel
11:00	Case Presentation	 <b>Wolfgang Guba</b> F. Hoffmann-La Roche
11:30	Group Discussion and Q&A	
12:00	Lunch Break	
Compound Screening		
13:00	From Hit Finding to Lead Optimization	 <b>Jörg Trappe</b> Novartis Pharma
13:45	Case Presentation	 <b>Marc Gitzinger</b> BioVersys
14:15	Group Discussion and Q&A	
14:45	Coffee Break	
Proof of Concept		
15:15	Target Validation from mice to men	 <b>Thomas Rückle</b> MMV
16:00	Case Presentation	 <b>Bettina Ernst</b> Preclin Biosystems
16:30	Group Discussion and Q&A	
Closing Keynote		
17:15	Navigating IP Issues	 <b>Bernhard Hostettler</b> IP Consultant
17:45	Group Discussion and Q&A	
18:00	Apéro & Networking	

# SBA ACADEMY

## Program Module 2: Nonclinical Development



Lausanne, Biopôle, March 22, 2013













Register at: [www.swissbiotech.org/anmeldungen/challenges\\_in\\_drug\\_discovery\\_and\\_development](http://www.swissbiotech.org/anmeldungen/challenges_in_drug_discovery_and_development)

Fee for members of SBA, switt, CTI start-up companies and academia: CHF 150/module, CHF 7500 for full package.

Fee for all others: CHF 950/module, CHF 3'800 for full package.

Contact: Swiss Biotech Association, Wengistrasse 7, 8004 Zürich, [bihlmann@swissbiotech.org](mailto:bihlmann@swissbiotech.org)

biopôle

Time	Title	Speaker
8:30–10:15	Registration	
	Introductory Keynote	
9:00	Pharma R&D: Issues and Perspectives	 <b>Kamel Besseghir</b> Debiopharm Group
9:45	Breakfast & Networking	
	Early Safety Tests	
10:15	Early Safety Tests	 <b>Manfred Schneider</b> Consultant
11:00	Case Presentation	 <b>Hasnaà Haddouk</b> Addex Therapeutics
11:30	Group Discussion and Q&A	
12:00	Lunch Break	
	Toxicity Studies	
13:00	Relevant Issues in Toxicity Studies	 <b>Rüdiger Häcker</b> Harlan Laboratories
13:45	Case Presentation	 <b>Carlo Chiavaroli</b> Voisin Consulting
14:15	Group Discussion and Q&A	
14:45	Coffee Break	
	Bioanalysis and DMPK studies	
15:15	Bioanalysis, Drug Metabolism and Pharmacokinetics in Drug Development: a Regulatory and Industrial Perspective	 <b>Valérie Nicolas</b> Debiopharm Group
16:00	Case Presentation	 case suggestion by speaker in process
16:30	Group Discussion and Q&A	
	Closing Keynote	
17:15	Issues in Quality Assurance	 <b>Claude Ammann</b> Consultant
17:45	Group Discussion	
18:00	Apéro & Networking	

# SBA ACADEMY

## Program Module 3: Manufacturing Process



Basel, Technologiepark, April 26, 2013














Register at: [www.swissbiotech.org/ansmeldungen/challenges\\_in\\_drug\\_discovery\\_and\\_development](http://www.swissbiotech.org/ansmeldungen/challenges_in_drug_discovery_and_development)

Fee for members of SBA, switt, CTI start-up companies and academia: CHF 150/module, CHF 750 for full package.

Fee for all others: CHF 950/module, CHF 3'800 for full package.

Contact: Swiss Biotech Association, Wengistrasse 7, 8004 Zürich, [bihlmann@swissbiotech.org](mailto:bihlmann@swissbiotech.org)



Time	Title	Speaker
8:30–10:15	Registration	
Introductory Keynote		
9:00	Pharma R&D: Issues and Perspectives	 <b>Hans Kocher</b> Novartis Pharma
9:45	Breakfast & Networking	
Dosage Form Design		
10:15	Dosage Form Design: From classical to “Right, First Time” workflow	 <b>Hans Leuenberger</b> University of Basel & CINAP
11:00	Case Presentation	 <b>Paul Ruffieux</b> SKAN
11:30	Group Discussion and Q&A	
12:00	Lunch Break	
Drug Substance Development		
13:00	Small Molecules vs. Biologics – Similarities and Differences	 <b>Robert Hett</b> Rapid Pharma Development
13:45	Case Presentation	 <b>Karlheinz Landauer</b> Celonic  <b>Thomas Schlatterer</b> Carbogen Amcis
14:15	Group Discussion and Q&A	
14:45	Coffee Break	
Other CMC Issues		
15:15	Solid State Criteria – the SSS Rule	 <b>Rolf Hilfiker</b> Solvias
16:00	Quality by Design and other Regulatory Aspects	 <b>Jutta Riedl</b> Swissmedic
16:30	Group Discussion and Q&A	
Closing Keynote		
17:15	Efficient Management of Outsourcing	 <b>Manfred Schulz</b> Lumavita
17:45	Discussion	
18:00	Apéro & Networking	

# SBA ACADEMY

## Program Module 4: Clinical Development



Lausanne, Biopôle, May 24, 2013













Register at: [www.swissbiotech.org/anmeldungen/challenges\\_in\\_drug\\_discovery\\_and\\_development](http://www.swissbiotech.org/anmeldungen/challenges_in_drug_discovery_and_development)

Fee for members of SBA, switt, CTI start-up companies and academia: CHF 150/module, CHF 750 for full package.

Fee for all others: CHF 950/module, CHF 3'800 for full package.

Contact: Swiss Biotech Association, Wengistrasse 7, 8004 Zürich, [bihlmann@swissbiotech.org](mailto:bihlmann@swissbiotech.org)

biopôle

Time	Title	Speaker
8:30–10:15	Registration	
Introductory Keynote		
9:00	Pharma R&D: Issues and Perspectives	 <b>Walid Abi-Saab</b> Shire Pharmaceuticals
9:45	Breakfast & Networking	
Clinical Phase I–II		
10:15	Phase I/II Clinical Trials in the Academic Setting – Benefits for Researchers and Industry	 <b>Michael Weisskopf</b> CTC Zürich
11:00	Case Presentation	 <b>Anya Hamman-Hänni</b> Cytos
11:30	Q&A	
12:00	Lunch Break	
Clinical Phase III		
13:00	Prove Safety & Efficacy in a large and patient Population	 <b>Stephanie Sauter</b> Five Office
13:45	Case Presentation	 <b>Marc Urich</b> Swiss Tropical & Public Health Institute
14:15	Q&A	
14:45	Coffee Break	
Pharmacovigilance & Trial Strategy		
15:15	Post Registration, Safety Monitoring, Planning & Coordinating Clinical Trials	 <b>Conrad Savoy</b> independent consultant
16:00	Case Presentation	 <b>Jean-Maurice Dumont</b> Debiopharm Group
16:30	Q&A	
Closing Keynote		
17:15	HFG – Federal Act on Research Involving Human Beings	 <b>Brigitte Meier</b> BAG
17:45	Discussion	
18:00	Apéro & Networking	

# SBA ACADEMY

## Program Module 5: Strategy Day



Zürich, Technopark Zürich, June 28, 2013














Register at: [www.swissbiotech.org/anmeldungen/challenges\\_in\\_drug\\_discovery\\_and\\_development](http://www.swissbiotech.org/anmeldungen/challenges_in_drug_discovery_and_development)


Fee for members of SBA, switt, CTI start-up companies and academia: CHF 150/module, CHF 750 for full package.

Fee for all others: CHF 950/module, CHF 3'800 for full package.

Contact: Swiss Biotech Association, Wengistrasse 7, 8004 Zürich, [bihlmann@swissbiotech.org](mailto:bihlmann@swissbiotech.org)



Time	Title	Speaker
8:30–10:15	Registration	
Introductory Keynote		
9:00	Pharma R&D: Issues and Perspectives	 <b>Francis Marsland</b> Biogen Idec
9:45	Breakfast & Networking	
Regulatory Strategy		
10:15	A Regulatory Strategy – From Discovery to Approval	 <b>Tobias Ostler</b> Dr. Regenold
11:00	Case Presentation	 <b>Hermann Schulze</b> Sucampo
11:30	Group Discussion and Q&A	
12:00	Lunch Break	
Human Ressources & Organising Growth		
13:00	HR Recruitment	 <b>Heiko Bruhn</b> Mediatum Schweiz
13:30	Personal Development	 <b>Carin Mittermayer</b> Santhera
14:00	Organisational Development	 <b>Christian Zahnd</b> Molecular Partners
14:15	Group Discussion and Q&A	
15:00	Coffee Break	
IP & Licensing		
15:30	Licensing & Partnering in the Life Science Sector	 <b>Babette Güldenpfennig</b> Kuros Biosurgery
16:00	Partnering Deals incl. outsourcing aspects	 <b>Titus Kretzschmar</b> Delenex Therapeutics
16:30	Group Discussion and Q&A	
Closing Keynote		
17:15	Due Dilligence	 <b>Thierry Briand</b> Thierry Briand Consulting
17:45	Discussion and Closing	
18:00	Apéro & Networking	



# SWISS BIOTECH™

**United forces lead to the summit**  
**1Nation1Cluster**

Swiss Biotech offers  
many paths to success.  
Following the best route  
prooves to be the safest.  
We can support your path  
to success in Switzerland.

[www.swissbiotech.org](http://www.swissbiotech.org)